Best Cancer Treatment Companies to Invest In – Top 3 List
Just imagine that one day, someone is going live, saying:’I found a cure for cancer. That could be the most exciting news for humanity in the entire human history. After all, human beings have had cancer throughout recorded history.
So, yes, clearly, that could be nice to hear. Meanwhile, there’s no cure for cancer, not even on the near horizon. But there are companies out there that specialize in cancer treatment. And these companies are worth investing in.
So, what about being in the right place at the right time? What about investing in a cancer treatment company or a cancer treatment portfolio? In this post, we suggest 3 top cancer treatment companies to invest in as well as cancer treatment ETFs and portfolios.
3 Best Cancer Treatment Companies in 2024 and Beyond
Here are the top 3 cancer treatment companies to invest in as of October 2024.
AstraZeneca (NASDAQ:AZN)
If you are looking for a blue-chip cancer treatment company, then AstraZeneca (NASDAQ:AZN) is the company of choice. This is a multinational pharmaceutical and biotech company that also specializes in various therapeutic areas, including cardiovascular, respiratory, central nervous system, and pain management.
The company has several collaborations, including a notable partnership with Merck (NYSE). Together, they introduced the PARP inhibitor LYNPARZA, used as both a monotherapy and in combination therapies to treat multiple cancer types, including certain breast, prostate, pancreatic, and ovarian tumors. LYNPARZA’s revenues are projected to reach US$4 billion by 2027, accounting for over 68 percent of the estimated global PARP inhibitor market by that year.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) develops treatments for various cancers, including cervical cancer, lung cancer, and melanoma. Based in San Carlos, California, this biopharmaceutical startup aims to develop tumor-infiltrating lymphocyte therapies against cancer.
The company’s stock has had a remarkable run over the past year, with a YoY return of nearly 188% and a YTD return of 22%. It currently holds an average rating of Strong Buy, with analysts setting an average price target of $20.42 per share.
Grail (NASDAQ: GRAL)
Grail (NASDAQ: GRAL) is another excellent cancer treatment company to invest in right now. The company essentially developed a blood test that can detect over 50 types of cancer and pinpoint the cancer’s location with nearly 90% accuracy. Also, the test boasts a low false positive rate of only 0.5%, according to Grail.
However, although Grail has quite a fascinating product to offer, the stock has been quite stagnant over the past few years, leaving an opportunity for those who wish to invest in cancer treatment firms. Its YoY return is just -0.81%, and its 5-years is -7.32%.
One of the key reasons for the stagnation in the GRAL stock is the unclarity of the company’s strategic direction as well as its inability to generate profits. Crucially, the company has released a positive report in Q2 2024, reporting a YoY return of 43%.
Investing in a Cancer Treatment Portfolio/ETF
Another option for those interested in investing in the cancer treatment industry is to find a cancer treatment portfolio or an Exchange Traded Fund (ETF). These funds typically collect several cancer treatment companies, allowing investors to spread the risk and get exposure to the cancer treatment industry.
Here are the top cancer treatment exchange-traded funds to invest in as of 2024:
- Tema Oncology ETF (CANC)
- Range Cancer Therapeutics Index ETF (CNCR)
- iShares Genomics Immunology and Healthcare ETF (IDNA)
Final Word
In sum, investing in cancer treatment stocks and ETFs can certainly be a good long-term investment. Each one of the companies mentioned above has an effective cancer treatment product that can generate good returns in the future. Having said that, it is advisable to take a look at the company’s reports before making any investment. Even though cancer treatment stocks are widely considered defensive, they can often be not profitable and, therefore, can lose value.
In that sense, if you have no particular cancer treatment stock you find interesting, you might want to consider investing in any of the ETFs above. This way, you can diversify your risk and get wider exposure to different oncology stocks.
